1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Included patients' main demographics, clinical characteristics, and DMT
Demographics No. of evaluable patients 232 Relapsing-emitting MS 177 (76.3%) Secondary-progressive MS 20 (8.6%) Primary-progressive MS 10 (4.3%) CIS (%) 21 (9.1%) RIS (%) 4 (1.7%) Age (mean) (yr) 46 (SD, 12.65) Sex (men/women) 81:151 EDSSa (median) (interquartile range) 2.5/2 Disease durationa (median) (interquartile range) 11/11 DMT efficacyb Moderatec 126 (60.9%) Highd 9 (4.3%) Very highe 36 (17.4%) No DMT 36 (17.4%)
Note:—CIS indicates clinically isolated syndrome; RIS, radiologically isolated syndrome; EDSS, Expanded Disability Status Scale; DMT, disease-modifying treatment.
↵a Patients with relapsing-remitting, secondary-progressive, or primary-progressive MS only.
↵b According to Dobson et al.28
↵c Includes dimethyl fumarate, glatiramer acetate, interferon-β 1-α, interferon-β-1b, and teriflunomide.
↵d Includes fingolimod, siponimod, and ozanimod.
↵e Includes alemtuzumab, cladribine, mitoxantrone, natalizumab, and ocrelizumab.